When did ResMed report Q3 2026 earnings?

ResMed (RMD) reported Q3 2026 earnings on April 30, 2026 after market close.

What were ResMed's Q3 2026 revenue and EPS?

ResMed reported revenue of $1.4B and diluted EPS of $2.86 for Q3 2026.

Did ResMed beat estimates in Q3 2026?

Revenue beat the consensus estimate of $1.4B by $11.5M. EPS beat the consensus estimate of $2.79 by $0.07.

How did ResMed's Q3 2026 results compare year-over-year?

Compared to the same quarter a year prior, revenue grew 10.8% from $1.3B a year earlier and diluted EPS grew 20.7% from $2.37.

Where can I find ResMed's Q3 2026 SEC filings?

You can read the 8-K earnings release (0001193125-26-197192) and the 10-Q periodic report (0000943819-26-000025) directly on SEC EDGAR. The filing index links above go to sec.gov.

ResMed RMD Q3 2026 earnings

Reported April 30, 2026 · After market close

Revenue$1.4BBeat by $11.5M Diluted EPS$2.86Beat by $0.07

Revenue estimate$1.4B

EPS estimate$2.79

Next report

Aug 6, 2026 (In 3 weeks)

Revenue estimate$1.5B

EPS estimate$2.90

Financials

Q3 2026

Income statement

See full

Revenue$1.4B+10.8%

Gross profit$891.0M+16.3%

Operating income$499.8M+17.3%

Net income$398.7M+9.2%

EPS (diluted)$2.74+10.5%

Balance sheet

See full

Cash & equivalents$1.7B+78.0%

Total debt$1.1B+29.8%

Total equity$6.5B+17.1%

Total assets$8.8B+16.1%

Cash flow

See full

Operating cash flow$554.1M-4.2%

CapEx$33.7M+61.8%

Free cash flow$520.5M-6.7%

Valuation & ratios

Valuation

as of 07/09/26

See full

Market cap$29.86B-0.5%

Enterprise value$29.3B-2.0%

P/E19.7×-3.2×

P/S5.4×-0.6×

Profitability

See full

Gross margin61.6%+2.8pp

Operating margin34.2%+2.1pp

Net margin27.4%+1.3pp

FCF margin31.7%+0.4pp

Returns & leverage

See full

Return on equity25.2%-0.6pp

Debt / equity0.2×0.0×

Current ratio3×-0.4×

Segments

By product

See full

Devices$1.5B+8.8%

Sleep And Breathing Health$1.3B+11.5%

Masks and other$1.0B+15.5%

Residential Care Software$170.9M+6.0%

By geography

See full

Global revenue$1.4B+10.8%

U.S., Canada and Latin America$818.7M+9.3%

Combined Europe, Asia and other markets$441.8M+15.9%

By segment

See full

Sleep and Breathing Health$1.3B+11.5%

Residential Care Software$170.9M+6.0%

Versus estimates

Revenue

Q3 2026$1.4BBeat by $11.5M

Q2 2026$1.4BBeat by $22.3M Q1 2026$1.3BBeat by $2.3M Q4 2025$1.3BIn line Q3 2025$1.3BBeat by $3.6M Q2 2025$1.3BBeat by $15.4M

Diluted EPS

Q3 2026$2.86Beat by $0.07

Q2 2026$2.81Beat by $0.07 Q1 2026$2.55Beat by $0.04 Q4 2025$2.55In line Q3 2025$2.37Miss by $0.01 Q2 2025$2.43Beat by $0.11

Ask the moment ResMed reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did ResMed report Q3 2026 earnings?: ResMed (RMD) reported Q3 2026 earnings on April 30, 2026 after market close.
What were ResMed's Q3 2026 revenue and EPS?: ResMed reported revenue of $1.4B and diluted EPS of $2.86 for Q3 2026.
Did ResMed beat estimates in Q3 2026?: Revenue beat the consensus estimate of $1.4B by $11.5M. EPS beat the consensus estimate of $2.79 by $0.07.
How did ResMed's Q3 2026 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 10.8% from $1.3B a year earlier and diluted EPS grew 20.7% from $2.37.
Where can I find ResMed's Q3 2026 SEC filings?: You can read the 8-K earnings release (0001193125-26-197192) and the 10-Q periodic report (0000943819-26-000025) directly on SEC EDGAR. The filing index links above go to sec.gov.